Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hearing Impairment
100%
Ototoxicity
81%
Cisplatin
62%
Childhood Cancer
44%
Oncology
43%
Pediatrics
37%
Sodium Thiosulfate
37%
Cancer Therapy
37%
Phase I Trials
37%
Hearing Assessment
37%
Germinoma
37%
DNA Template
37%
N-Acetylcysteine
37%
Intracranial Tumor
37%
Hearing
24%
Arm
18%
Audiometry
18%
Platinum
18%
Chemotherapy
18%
Cancer Treatment
16%
Cohort Effect
12%
Malignant Neoplasm
10%
Neuro-Oncology
10%
Liver Tumor
9%
Adverse Event
8%
Late Effect
6%
Rank Sum Test
6%
Auditory Threshold
6%
Quality of Life
5%
Cancer
5%
Endocrine Disease
5%
Laboratory Test
5%
Cognitive Defect
5%
Prevalence
5%
Primary Health Care
5%
Sequela
5%
Clinical Management
5%
Brain Metastasis
5%
Tinnitus
5%
Financial Toxicity
5%
Patient Referral
5%
Agents Acting on the Eye
5%
Vascular Disease
5%
Sleep Disorder
5%
Carboplatin
5%
Awareness
5%
Mood Disorder
5%
Comorbidity
5%
Physical Disability
5%
Patient Care
5%
Keyphrases
Cisplatin-induced Hearing Loss
60%
Otoprotection
44%
Hearing Loss in children
37%
Phase I Trial
37%
N-acetylcysteine
37%
Bone Conduction
37%
Cranial Orthosis
37%
Headband
37%
Digital Technology Application
37%
Global Template
37%
Control Phase
37%
Pediatric
37%
Brain Tumor Survivors
37%
Helmet
22%
Otoprotectant
21%
Audiologic
15%
Quality of Life
15%
Sodium Thiosulfate
15%
Cisplatin
13%
Control Arm
9%
International childhoods
9%
Deep Integration
7%
Historical Paradigms
7%
Helmet Therapy
7%
Deformational Plagiocephaly
7%
Conductive Hearing Loss
7%
Innovative Study
7%
Systemic Agents
7%
Novel Endpoints
7%
Childhood Cancer Treatment
7%
Patient's Family
7%
Lifelong Consequences
7%
Family Advocates
7%
Trial Design
7%
Trial Development
7%
Late Effects
7%
Trial Efficiency
7%
Agent-based
7%
Published Data
7%
Research Trials
7%
Central Review
7%
Mechanistic Considerations
7%
Testing Battery
7%
Translational Research
7%
Cancer Survivors
7%
Modifying Effect
7%
Limited Samples
7%
Genetic Susceptibility
7%
Collective Experience
7%
Tympanic
7%
After childhood
7%
Early Phase Clinical Trials
7%
Grading Criteria
7%
Ototoxicity
7%
Data Experience
7%
Recommended Phase 2 Dose
6%
Assessment Characteristics
6%
Frequency Distortion
6%
Maximum Tolerated Dose
6%
95% Confidence Interval
6%
Deactivator
5%
Nursing and Health Professions
Hearing Impairment
84%
Ototoxicity
83%
Pediatrics
75%
Childhood Cancer
59%
Platinum
55%
Cisplatin
54%
Sodium Thiosulfate
52%
Cancer Therapy
45%
Pilot Study
44%
Bone Anchored Hearing Aid
37%
Cranial Orthosis
37%
Digitization
37%
Germ Cell Tumor
37%
Economic and Social Development
29%
Quality of Life
20%
Audiometry
18%
Efficacy
18%
Malignant Neoplasm
18%
Chemotherapy
18%
Liver Tumor
9%
Sample Size
7%
Genetic Susceptibility
7%
Conduction Deafness
7%
Plagiocephaly
7%
Turnaround Time
6%
Rank Sum Test
6%
Auditory Threshold
6%
Carboplatin
5%
Clinical Management
5%
Tinnitus
5%
Adverse Event
5%